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Cancer is a complex disease, with multiple genes in 
diverse pathways involved in its initiation, progression, 
invasion and metastasis. In fact, it is widely accepted 
that the sequential accumulation of mutations that 
activate oncogenes and disrupt tumour suppressor 
genes, combined with multiple cycles of clonal 
selection and evolution facilitate the process of 
carcinogenesis. It has been estimated that disruption of 
about six cellular processes are required for 
transformation (Hanahan and Weinberg, 2000). 
However, a recent comprehensive sequence evaluation 
of colon and breast cancer genomes hints that this 
number may be even higher (9 for breast, 12 for colon) 
than previously estimated (Sjoblom et al., 2006). If this 
model holds true then the rate-limiting step in the 
process of carcinogenesis would be the rate at which 
new mutations occur and any factor that influences this 
rate should have an effect on the rate of carcinogeesis.  
Genetic instability refers to a set of events capable of 
causing unscheduled alterations, either of a temporary 
or permanent nature, within the genome. This term 
encompasses diverse genetic changes, which can be 
classified in a variety of ways. For simplicity we will 
categorize them into two major groups, instability 
occurring at the chromosomal level and at the 
nucleotide level. Instability at the nucleotide level 
occurs due to faulty DNA repair pathways such as base 
excision repair and nucleotide excision repair and 
includes instability of microsatellite repeat sequences 
(MSI) caused by defects in the mismatch repair 
pathway. The second form or chromosomal instability 
(CIN), defines the existence of accelerated rate of 
chromosomal alterations, which result in gains or losses 
of whole chromosomes as well as inversions, deletions, 
duplications and translocations of large chromosomal 
segments. Aneuploidy, which refers to an abnormal 
karyotype is a hallmark of many cancer cells and is 
thought to develop as a result of CIN. The observation 
that cancer cells harbour an abnormal number of 
chromosomes was made almost a century ago (Boveri, 
1914; von Hansemann, 1890) since then we have come 
a long way in understanding the causes behind this type 
of instability. To date several pathways and processes 
have been implicated in CIN including :  
a) pathways involved in telomere and centromere 
stability,  
b) cell cycle checkpoint pathways and kinases, 
c) pathways regulating diverse proteins via post-
translational modifications, 
d) sister chromatid cohesion and chromosome 
segregation, and  
e) centrosome duplication (Jefford and Irminger-
Finger, 2006).  
Genetic instability is a very broad topic that 
encompasses varied fields of biology. Hence, in this
article we will focus on nucleotide instability including 
microsatellite instability; the role of epigenetic 
modifications, telomeres and the environment in 
genetic instability; and the role of genetic instability in 
cancer stem cells. For further details on chromosomal 
instability please refer to the Deep Insight article titled 
Chromosomal instability by David Gisselsson.  
DNA repair defects 
Cells are exposed to many damaging insults capable of 
causing aberrations in DNA. These include 
environmental insults such as ultraviolet (UV) light, X-
rays and genotoxic chemicals, as well the by-products 
of endogenous processes such as reactive oxygen 
species (ROS) and lipid peroxides. In addition, some 
chemical bonds in DNA tend to spontaneously break 
down under physiologic conditions, such as when 
spontaneous hydrolysis of nucleotides occurs resulting 
in abasic sites (Hoeijmakers, 2001). In order to repair 
these errors and restore the integrity of the genome, the 
cell has in place a range of overlapping DNA repair 
networks. Some of the best evidence for the role of 
genetic instability in tumourigenesis comes from 
examples where mutations that cause defects in dna 
repair mechanisms lead to syndromes of cancer 
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susceptibility. Some of the common examples studied 
to date will be discussed below.  
Mismatch Repair and Microsatellite Instability 
Mismatch repair (MMR) has a central role in 
maintaining genomic stability by repairing DNA 
replication errors and inhibiting recombination betw en 
homologous sequences (Bellacosa, 2001). It is a post-
replicative mechanism capable of eliminating base-base 
mismatches and insertion/deletion loops that arise 
during DNA synthesis. In the mammalian MMR 
system two heterodimeric complexes recognize 
mispaired bases; the hMSH2-hMSH3 (MutSs) 
complex, which preferentially recognizes insertion/ 
deletion loops; and the hMSH2-hMSH6 (MutSa) 
complex, which recognizes both base-base mispairs 
and insertion/ deletion loops. Two other proteins, 
hMLH1 and hPMS2, form a heterodimer (MutLa) that 
is then able to bind to the previously mentioned 
hMSH2 heterodimers. This complex is thought to 
interact with and recruit other proteins required for the 
repair process including Exo1, PCNA, RPA and Polg. 
In addition, a recent report demonstrated that MutLa is 
a latent endonuclease that is activated in the presence 
of a mismatch, MutSa, RFC, PCNA and ATP (Kadyrov 
et al., 2006). hMLH1 has been shown to form two other 
heterodimers, MutLs and MutLg, with the hPMS1 and 
hMLH3 proteins respectively. The roles of these two 
complexes in post-replicative error repair remains 
largely inconclusive, although it is believed that each 
could act as a "backup" for MutLa if the need arose. 
MMR improves the fidelity of DNA biosynthesis 100-
1000 fold and reduces the error rate to one error per 
1010 bases (Modrich and Lahue, 1996). Defective 
MMR results in mirosatellite instability (MSI), 
characterized by the expansion or contraction of the 
number of tandem repeats, due to polymerase slippage 
at the many microsatellite loci that occur throughout 
the genome. 
Germline mutations in the MMR genes are associated 
with the inherited cancer syndrome, hereditary non-
polyposis colorectal cancer (HNPCC). Instability of 
microsatellite repeats is seen in tumours of as many as 
85% of patients with HNPCC, making it a hallmark 
feature of this syndrome (Aaltonen et al., 1993; 
Aaltonen et al., 1994). HNPCC, which accounts for 
about 2% of all CRC cases, is one of the most common 
cancer predisposition syndromes. It is an autosomal 
dominant disorder characterized by the development of 
cancer in the colon as well as in extra-colonic sites 
including the endometrium, stomach, urinary tract, 
ovaries, small bowel and brain. MMR deficiency has 
also been shown to give rise to sporadic colorectal, 
endometrial and gastric cancers. Defective mismatch 
repair increases the likelihood of mutations in genes 
containing repeat sequences that regulate growth, 
differentiation or apoptosis. Somatic mutations of 
several genes including TGFBR2, BAX, TCF4, 
AXIN2, and PTEN are found in MSI positive cancers.  
To date there have been reports of families with 
individuals who have homozygous mutations in the 
mismatch repair genes MLH1, MSH2, MSH6 and 
PMS2. Such individuals develop several congenital 
abnormalities including haematopoietic malignancies, 
pediatric brain cancers, childhood leukemia, and 
HNPCC-related cancers and multiple cafe-au-lait spos, 
a common characteristic of neurofibromatosis type 1 
[De Vos et al., 2004; Gallinger et al., 2004; Menko et 
al., 2004; Trimbath et al., 2001; Whiteside et al., 2002; 
De Vos et al., 2006). This phenotype manifests in an 
autosomal recessive fashion, because a mutant allele is 
inherited from each parent. In addition, there have be n 
reports of individuals carrying compound heterozygous 
PMS2 mutations who develop Turcot syndrome (De 
Rosa et al., 2000). This syndrome is defined by the 
presence of brain tumors and multiple 
adenomas/colorectal cancers that occur at an early age 
and is associated with mutations in the APC and MMR 
genes.  
Nucleotide Excision Repair 
Nucleotide excision repair (NER) has a broader 
specificity in that it is able to recognize lesions a  
diverse as disturbances in the double helix 
conformation that are caused by UV light, to chemical 
damage that gives rise to DNA cross links/bulky 
adducts. The NER pathway is a multi-step process and 
as many as 30 proteins assemble at the damaged site in
a stepwise fashion (Hoogervorst et al., 2005). 
Individuals born with defects in the NER pathway 
develop a syndrome known as Xeroderma 
Pigmentosum (XP). Inherited defects in any one of the 
7 nucleotide excision repair XPA-XPG genes as well as 
XPV (a non NER gene) have been implicated in this 
disease (Hoeijmakers, 1994). XP patients have a very 
high susceptibility to developing cancer in areas of kin 
exposed to the sun. The median age at which skin 
tumours arise in these patients is 8 years, compared 
with a average of 60 years observed in the normal 
population (Kraemer, 1997). In addition a subset of XP 
patients show neurological defects and emerging 
evidence appears to indicate that the immune system of 
XP patients is impaired due to UV exposure (Morison 
et al., 1985; Norris et al., 1990; Dupuy and Lafforet, 
1974; Gaspari et al., 1993; Jimbo et al., 1992). This 
may indicate defective immune surveillance or 
increased susceptibility to UV-induced 
immunomodulation, which may contribute to the 
increased susceptibility to skin cancer (Hoogervorst et 
al., 2005). Two other syndromes have been associated 
with defective NER, the first being Cockayne 
syndrome characterized by neurological defects and 
sun sensitivity but no predisposition to skin cancer 
(Nance and Berry, 1992). The second syndrome 
trichothiodystrophy is defined by patients with brittle 
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hair caused by a sulphur deficiency, in addition to other 
features such as mental retardation and small stature 
(Itin et al., 2001; Bergmann and Egly, 2001). 
Base Excision Repair 
Base excision repair (BER) is mainly responsible for 
repairing damage induced by endogenous metabolic 
processes such as methylation, deamination, reactiv 
oxygen species (ROS) and hydrolysis (Wood et al., 
2001). Multiple proteins contribute to BER pathway 
and enable it to correct non-bulky damaged 
nucleotides, abasic sites as well as single-strand breaks. 
The process is initiated by DNA glycosylases specific 
for various types of damage, which recognize and 
cleave the N-glycosylic bond that connects the 
damaged base to the DNA backbone (Barnes et al., 
1993). To date, 11 such DNA glycosylases have been 
identified in mammals (Chan et al., 2006). Reactive 
oxygen species can modify the C8 position of Guanine 
to form 7, 8-dihydro-8-oxoguanine (8-oxoG), a major 
product of such damage. 8-oxoG is highly mutagenic 
and is able base pair with adenine and cause G:C->TA 
transversions (Shibutani et al., 1991). The glycosylases 
most commonly involved in the removal of 8-oxoG are
OGG1, MYH and MTH1. It was discovered recently 
that biallelic inactivation of MYH can lead to an 
autosomal recessive form of inherited colorectal cancer 
known as MYH-associate polyposis (MAP) (Al-Tassan 
et al., 2002). This came as a surprise to many, as unlike 
MMR and NER, no inherited defects in these genes had 
been reported prior to this (Al-Tassan et al., 2002). 
Role of Epigenetic Modifications in 
Genetic Instability 
In addition to the sequence alterations and 
chromosomal aberrations discussed above, epigenetic 
modifications that affect both DNA and the associated 
chromatin are capable of influencing gene expression 
and the stability of the genome. An important point to 
bear in mind is that although epigenetic modifications 
are mitotically heritable, they are in a state of cnstant 
flux within the lifetime of an individual. The possible 
contribution of the best-studied epigenetic mechanisms 
to genetic instability will be discussed below. 
Methylation in Tumourigenesis 
DNA methylation or the covalent modification of the 
C-5 position of cytosine residues occurs primarily at 
the short stretches of CG dinucleotides known as CpG 
islands. Recent estimates suggest that there are at least 
29,000 such regions in the human genome, many of 
which surround the 5' ends of genes (Lander et al., 
2001). In bacteria, methylation is thought to have 
evolved as a defense against foreign DNA. On the 
contrary, in eukaryotes methylation is thought to play a 
role in regulating gene expression and in silencing 
repeat elements in the genome (Jacobsen, 1999). In 
normal cells the pattern of expression is stably 
maintained following DNA replication and cell division 
by a maintenance enzyme, DNA methyltransferase, 
(DNMT1). The establishment of DNA modifications is 
thought to be a highly random event (Whitelaw and 
Whitelaw, 2006), and could be instrumental in 
contributing to genetic instability. This is illustra ed by 
the example of DNMT1, which has an estimated error 
rate of 5%, as well as a small rate of de novo 
methylation (Goyal et al., 2006; Vilkaitis et al., 2005).  
The first epigenetic mechanism implicated in 
carcinogenesis was DNA hypomethylation (Feinberg 
and Tycko, 2004). In addition, there have been reports 
of age related decreases in DNA methylation levels that 
occur in a tissue specific manner (Feinberg and 
Vogelstein, 1983; Golbus et al., 1990). It is likely that 
these changes contribute to the age-related increase in 
incidence of illnesses, such as carcinogenesis and 
autoimmunity (Richardson, 2003). Examples of genes 
hypomethylated in cancer include cyclin d2 in gastric 
carcinoma (Oshimo et al., 2003), Ha-RAS in lung and
colon cancer (Feinberg and Vogelstein, 1983) and 
Maspin and S100P in pancreatic cancer (Sato et al., 
2004). Several studies have implicated genomic 
hypomethylation in the genetic instability seen in many 
cancers. In a recent study of colorectal carcinomas it 
was shown that genome-wide hypomethylation is 
strongly correlated with chromosomal instability 
(Rodriguez et al., 2006), indicating the potential role of 
hypomethylation in destabilizing the genome.  
CpG islands commonly occur in the promoter regions, 
thus hypermethylation of this region has been shown to 
silence gene expression (Bird, 2002). This was first 
identified in the retinoblastoma protein (Rb) followed 
by promoter hypermethylation of several other tumour 
suppressor and cell-cycle regulatory genes (Greger t 
al., 1989). It is believed that hypermethylation too is an 
early event that may precede the neoplastic process 
(Momparler, 2003; Nephew and Huang, 2003). A 
prime example of the role of hypermethylation in 
contributing to genetic instability is hMLH1 
inactivation, where promoter hypermethylation is 
thought to be primarily responsible for approximately 
15% of sporadic colorectal cancers associated with 
microsatellite instability (Kane et al., 1997; Herman et 
al., 1998). In a study by Costello et al. (Lander et al., 
2001), 1184 unselected CpG islands were screened in 
98 primary human tumours using restriction landmark 
genomic scanning (RLGS). This study found that on 
average about 600 CpG islands were aberrantly 
methylated in tumours, indicating the potentially vast 
number of genes likely to be aberrantly expressed due 
to this mechanism.  
Methylation also plays an important role in inactiva ng 
one copy of the X chromosome, so that equal gene 
dosage is maintained in the somatic cells of males nd 
females (Park and Kuroda, 2001). Imprinting refers to 
the phenomenon by which only the maternal or paternl 
allele of certain genes are expressed and the second 
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allele is suppressed via methylation (Ferguson-Smith 
and Surani, 2001). Therefore demethylation of such 
imprinted genes can lead to a situation where both 
alleles are expressed (Feinberg, 2000; Feinberg et al., 
2002). This has been shown to contribute to 
malignancies by activating a normally silent copy of 
the gene as in the case of IGF2 (Rainier et al., 1993). 
Aberrant imprinting can also silence a normally active 
copy of a gene involved in growth inhibition as shown 
with p57kip (Thompson et al., 1996). Loss of 
imprinting has also been shown to contribute to certain 
congenital syndromes such as the Beckwith-
Wiedemann Syndrome, Prader-Willi Syndrome (PWS) 
and Angelman's Syndrome (AS) (Maher and Reik, 
2000; Reik et al., 2001). Beckwith-Wiedmann 
syndrome occurs due to loss of imprinting on 
chromosome 11p, and is characterized by pre- and 
post-natal overgrowth syndrome, often accompanied by 
exomphalos and a predisposition for childhood tumours 
(Paulsen and Ferguson-Smith, 2001). Loss of 
imprinting on chromosome 15q of the paternal and 
maternal alleles, lead to PWS and AS respectively. 
PWS is characterized by mild mental retardation, short 
stature and obesity, while AS is characterized by ataxi , 
severe mental retardation accompanied by a lack of 
speech, hyperactivity and a predisposition for 
inappropriate bouts of laughter (Paulsen and Ferguson-
Smith, 2001). 
Histone modification 
Chromatin, which consists of repeating units called 
nucleosomes, is the packaged form of DNA present in 
the eukaryotic cell. Each nucleosome consists of DNA 
that is wrapped tightly around a group of conserved, 
highly basic proteins known as histones. Histones can 
be covalently modified by acetylation, methylation, 
phosphorylation, ubiquitination and Poly-ADP 
ribosylation, which ultimately influence the tightness of 
the protein-DNA interaction and can create a code that 
can be recognized by chromatin remodeling complexes 
(Strahl and Allis, 2000; Turner, 2002). This idea of a 
histone code suggests that specific patterns of 
modifications are read like a molecular bar code, 
resulting in the recruitment of cellular machinery that 
alter the chromatin state (Cosgrove and Wolberger, 
2005). The role of histone modification and chromatin 
remodeling in the carcinogenic process is a rapidly 
evolving field. To date histone acetylation and 
methylation have been implicated in cancer.  
It is the interplay between histone acteylases (HATs) 
and histone deacetylates (HDACs) that determine the 
precise balance of acetylation within the nucleus. 
Abnormal HDAC activity has been commonly 
observed in haemotological malignancies (Espino et al., 
2005). Studies done in these cancers have shown that 
fusion proteins such as RAR-PML and RAR-PLZF can 
recruit HDACs, which in turn lead to aberrant 
transcriptional repression that halts differentiation (de 
Ruijter et al., 2003; Hong et al., 1997). It has been 
proposed that a dynamic relationship exists between 
histone modifications, chromatin structure and DNA 
methylation (Szyf et al., 2004; Ting et al., 2004). For 
example it has been shown that histone acetylation nd 
gene activation, results in DNA demethylation (Szyf et 
al., 2004), while the opposite situation where low 
steady state level of histone acetylation and 
methylation, results in the recruitment of DNMT1 and 
DNA methylation of regulatory regions (Espino et al., 
2005). Thus, it is mechanistically possible that skewed 
regulation of this inter-relationship could lead to
genetic instability. 
The role of the environment in 
genetic instability 
Despite the many checkpoints and repair processes the 
cell has in place to prevent the occurrence and 
propagation of errors, genetic instability is a 
widespread phenomenon observed in many cancers. 
Thus, it appears likely that the environment in which 
these cancers arise somehow selects for and facilitates 
the clonal expansion of cells that show instability in 
their genome. This point is supported by the 
observation that colorectal tumours, which show an 
MSI or CIN phenotype exclusively, are located in 
anatomically distinct regions. MSI tumours are 
localized in the proximal section of the intestine, while 
CIN tumours are more frequently seen in the distal 
colon and rectum (Lengauer et al., 1998; Lindblom, 
2001). This review will therefore briefly summarize 
what is currently known about the role of the 
macroenvironment, specifically dietary factors and the
microenvironment, specifically hypoxia in the 
development of genetic instability. 
It is possible that environmental agents are able to 
instigate the process of instability, as illustrated by 
work done in colorectal carcinogenesis. Heterocycli 
amines (HAA) are carcinogens that are a common 
product of cooking beef, pork, poultry and fish at high 
temperatures. A study by Wu et al., demonstrated that 
patients with MSI positive cancers had significantly 
higher dietary exposure to heterocyclic amines, as 
determined by the preference for well-done meat and 
the frequent use of techniques that produces HAA (Wu
et al., 2001). 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine or PhIP, the most abundant heterocyclic 
amine in the western diet, is a bulky adduct forming 
agent that is able to cause a variety of cancers in 
experimental animals (Ghoshal et al., 1994; Layton et 
al., 1995; Shirai et al., 1997; Tudek et al., 1989). 
Another powerful rodent carcinogen is MNNG (N-
methyl-N'-nitro-N-nitrosoguanidine) (Sugimura and 
Terada, 1998). An alkylating agent, it is able to 
preferentially methylate the O6 position of 
deoxyguanosine residues in DNA. Gastrointestinal cells 
are continually exposed to both PhIP and MNNG at 
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varying concentrations. In a study undertaken to 
determine if carcinogen exposure can influence the 
type of instability seen in cells, it was found that cells 
resistant to PhIP, developed a chromosomal instability 
or CIN phenotype, while cells resistant to MNNG 
exhibited MSI and associated mismatch repair defects 
(Bardelli et al., 2001). This data suggests that exposure 
to certain dietary carcinogens, may in fact select for 
cancer cells with distinct types of genetic instability 
and vice versa (Bardelli et al., 2001).  
Role of tumour microenvironment in genetic 
instability 
The tumour microenvironment has been proposed to 
contribute to the increased genetic instability seen in 
cancer cells. Several studies have lent support to this 
notion, including a study that demonstrated a higher 
rate of genomic instability of mouse cells when grown 
in vivo as subcutaneous tumour implants in syngeneic 
mice, as measured using an EGFP reporter gene and a
genomic minisatellite locus (Li et al., 2001). More 
specifically, hypoxia has been singled out as a major 
microenvironmental factor. Hypoxia, which appears to 
occur transiently within the tumour microenvironment, 
has been shown to lead to cycles of hypoxia and 
reoxygenation (Bindra and Glazer, 2005). This is 
thought to lead to DNA damage as a result of reactive 
oxygen species (ROS) and the enzyme superoxide 
dismutase. In addition to ROS leading to the formation 
of 8-oxoG, and accumulating evidence suggest a role 
for oxygen and ROS in causing single and double 
strand breaks (Bindra and Glazer, 2005). In addition o 
its ability to cause aberrations in DNA, these cycles of 
hypoxia and reoxygenation have been shown to affect 
DNA synthesis, by both interrupting this process and 
by leading to over-replication after reoxygenation 
(Bindra and Glazer, 2005; Cuvier et al., 1997; Young. 
and Hill, 1990; Young et al., 1990). Other studies have 
found that it is hypoxia induced gene amplification f 
p-Glycoprotein that is responsible for the observed 
resistance to adriamycin and doxorubicin (Luk et al.,
1990; Rice et al., 1987), indicating that gene 
amplification may also be caused by hypoxia. 
Furthermore, emerging evidence suggests that hypoxia 
can influence the integrity of the genome by impacting 
upon DNA repair pathways. As described above, 
MLH1 is one of the key genes involved in mismatch 
repair. It was shown that hypoxia downregulates the 
expression of the MLH1 gene at the transcriptional 
level and this was thought to occur via chromatin 
remodeling, as treatment with an histone deacteylas 
inhibitor prevented the aforementioned decrease 
(Mihaylova et al., 2003). It has also been demonstrated 
that hypoxia enriches for MMR deficient cells 
(Hardman et al., 2001). Thus, DNA damage, defective 
DNA synthesis, gene amplification and the 
deregulation of DNA repair pathways all appear to be 
mechanisms by which hypoxia contributes to genetic 
instability. Little is still known about other 
microenvironmental factors that may lead to instability. 
However, it has been suggested that the tumour 
microenvironment may represent in mammalian cells a 
conserved evolutionary mechanism that increases the 
rate of mutation in response to cellular stresses, which 
preferentially gives cancer cells a survival advantage 
(Bindra and Glazer, 2005). 
Telomeres and Genetic Instability 
One mechanism that can bring about chromosomal 
instability (CIN) is telomere loss. Although CIN is not 
addressed in detail in this paper, the role of telom res is 
briefly summarized to highlight the important role it 
may play in carcinogenesis and the implications it may 
have in the field of genetic instability.  
Telomeres refer to the segments of DNA bound by 
specific proteins that cap the ends of chromosomes and 
in doing so acts as a buffer to prevent loss of valuable 
genomic sequence during replication (Hoeijmakers, 
2001), as well as to prevent chromosomes fusing at the 
ends (Jefford and Irminger-Finger, 2006). A RNA 
primer is required for the process of DNA replication. 
Thus, when replication proceeds from the 5'->3' 
direction, it leaves a stretch of unreplicated DNA at the 
5' end. This leads to a gradual loss of telomeric repeats 
and the consequent shortening of telomeres by about 
50-200 base pairs, after each round of replication 
(Jefford and Irminger-Finger, 2006). A specific 
enzyme, telomerase, maintains the telomere length. 
Telomerase consists of two main components; the 
reverse trancriptase component (hTERT), which is only
expressed in cells where telomerase activity is preent; 
and the ribonucleoprotein moiety (hTERC/hTR), which 
is expressed ubiquitously in all cells. In adults, 
telomerase activity has been observed only in immature 
germ cells, certain stem/progenitor cells and in a subset 
of somatic cells such as human fibroblasts.  
Telomerase is suppressed in the majority of somatic 
cells leading to the continuing telomere attrition, which 
leads to irreversible cell-cycle arrest known as 
replicative cell senescence. It has been demonstrated 
that primary human fibroblasts that have lost the ability 
to senesce, display telomere shortening and eventually 
enter a crisis stage that culminates in chromosome 
fusion, aneuploidy and cell death (Counter et al., 1992). 
It has been proposed that it is therefore important for 
cancer cells to regain the ability to maintain telomeres, 
in order to avoid senescence and extensive 
chromosome fusion during crisis (Counter et al., 1992; 
Harley, 1995). In fact it has been shown that about 85-
90% of human cancers have reactivated telomerase and 
are able to maintain telomere length (Jefford and 
Irminger-Finger, 2006). Interestingly cancer cells that 
are deficient for telomerase activity are able to maintain 
telomere length via a mechanism known as alternative 
lengthening of telomeres or ALT. It has been suggested 
that the ALT mechanism makes use of DNA repair 
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pathways and recombination to maintain telomere 
length (Reddel, 2003). Thus, whichever mechanism 
employed by the cell, it appears that maintaining 
telomere length is critical for tumourigenesis and 
cellular immortalization (Jefford and Irminger-Finger, 
2006). Telomere maintenance is also required for 
chromosomal instability. Given that cancer cells 
inevitably display properties of telomere maintenance 
and genetic instability, it has been proposed that 
telomere loss could be either a cause or a consequence 
of genetic instability (Jefford and Irminger-Finger, 
2006), or perhaps be involved in both.  
However, conflicting with this view is the observation 
that the telomeres of invasive human cancers are often 
shorter than their normal counterparts (de Lange, 
1995). Studies in telomerase deficient mice (mTERC-/-
) provided a plausible explanation to this paradox (Ju 
and Rudolph, 2006). In these mice telomere shortening 
induced chromosome instability and in doing so 
increased the rate of tumour initiation (Rudolph et al., 
2001). At the same time it was seen that telomere loss
can inhibit tumour progression and the development of 
macroscopically advanced tumours (Rudolph et al., 
2001; Gonzalez-Suarez et al., 2000; Greenberg et al., 
1999; Rudolph et al., 1999). This indicates that the
timing at which the telomeres shortening occurs plays a 
crucial role in cancer development (Meeker et al., 
2004). In fact it was found that 88.6% of precursor 
lesions known as intraepithelial neoplasia lesions 
display shortening of telomeres (Meeker et al., 2004). 
Cancer Stem Cells and Genetic 
instability 
The stem cell model of carcinogenesis has been rapidly 
growing in popularity. The American Association for 
Cancer Research Stem Cell Workshop defined a cancer 
stem cell as a cell within the tumour that possesses th  
capacity to self-renew, and in doing so gives rise to the 
heterogeneous lineages that comprise the tumour. 
Cancer cells may arise therefore from tissue stem clls
that have acquired mutations that render them 
cancerous, or it may be a more differentiated i.e. 
progenitor cell that may have "re-acquired" stem cell
like properties due to mutations (Clarke et al., 2006). 
Either scenario is different from the widely accepted 
stochastic model of carcinogenesis. Cancer stem cells
or cancer initiating cells have been identified to date in 
acute myelogenous leukemia (Bonnet and Dick, 1997), 
breast tumours (Al-Hajj et al., 2003), brain tumours 
(Singh et al., 2003; Singh et al., 2004) and most 
recently in a subset of colon tumours (O'Brien et al., 
2006). The discovery of the existence of cancer 
initiating cells raises some very important questions 
regarding whether genetic instability exists within these 
cells and what role if any it plays in these cells.  
There is an increased likelihood that exogenous and 
endogenous environmental agents cause a greater 
degree of genetic and epigenetic changes in stem cells;
as opposed to their differentiated counterparts, who by 
their very definition have shorter life spans. This is a 
fairly novel field, and much more research needs to be 
undertaken to determine the relationship between 
genetic instability and cancer stem cells. However 
some preliminary evidence comes from work done in 
haematological malignancies and telomere instability. 
Haematological neoplasia can be divided in to three 
stages, pre-malignant, chronic and acute, with the last 
being the most advanced stage. Telomere loss was 
shown to be rapid during the progression of chronic 
myeloid leukemia, in fact patients in the late chronic 
phase had shorter telomeres than those in early chroni  
phase (Brummendorf et al., 2001). In addition patients 
with pre-malignant disease with shorter telomeres had
more cytogenetic abnormalities (Ohyashiki et al., 1999) 
and a poorer prognosis with increased rates of leukemic 
transformation (Sieglova et al., 2004). These 
observations suggest that shortening telomeres can 
bring about genetic instability in cancer stem cells, 
which is further supported by the observation that 
telomere shortening occurs very early in carcinogenic 
cascade, indicating the likelihood that this process 
occurs in cancer stem cells. Additionally, progression 
of pre-malignant disease to acute stage was shown t 
correlate with telomerase activation (Ohyashiki et al.,
2001). Together these observation implicate telomere 
attrition and telomerase reactivation as risk factors f r 
the malignant transformation of stem cells (Ju and 
Rudolph, 2006). On a separate note, loss of 
heterozygosity of cancer related genes in mammary 
stem cells have been shown to contribute to genetic 
instability in progeny cells and result in subsequent 
breast cancer development (Al-Hajj et al., 2003; Deng 
et al., 1996; Smith and Boulanger, 2002; Nguyen and 
Ravid, 2006). This observation also supports the notio  
that the theories of genetic instability and cancer st m 
cells are not mutually exclusive. 
Summary and Conclusion 
It is well documented that the sequential accumulation 
of mutations in tumour suppressors and oncogenes are 
required for the process of tumourigenesis to proceed. 
Any event(s) that accelerates the spontaneous rate of 
alterations in the cells supports this process, illustrated 
by the prevalence of genetic instability in cancer lls. 
DNA repair processes play a critical role in repairing 
damaged DNA, and in ensuring faithful transmission of 
genetic material. Thus, it comes as no surprise that 
inherited defects of genes in these pathways, lead to 
several disorders, most of which increase susceptibility 
to cancer by many fold, and maybe evident by the early 
age at diagnosis of cancer in these in patients. In 
addition to genetic alterations, epigenetic modifications 
such as methylation and histone modification have 
been shown to bring about genetic instability. In 
addition, it is likely that the prolonged exposure to 
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environmental agents and/ or processes may, in concert 
with individual genetic factors determine the 
establishment of tumours. Despite these observations, 
the existence of subsets of tumours that lack an 
identifiable form of instability has led to skepticism 
regarding the need for genetic instability in the process 
of cellular transformation. However, this may indicate 
that the importance of genetic instability in 
carcinogenesis differs based on several factors 
including an individual's genetic background, tissue of 
interest, baseline mutation rate, environmental 
exposure, age and time of onset. There also remains the 
question of whether genetic instability is the driving 
force behind the process of tumourigenesis or if its 
simply a bystander effect of the process. Thus the 
precise role of genetic instability in the various cancers 
needs to be defined further. An additional challenge is 
posed by the prospective identification of cancer st m 
cells, which call for theory of genetic instability o be 
reviewed in a new light. 
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